Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03838900 · ClinicalTrials.gov registry record
The Loop Observational Study
A clinical trial of Diabetes Mellitus, Type 1, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- 1,212
- Enrollment target
- 1
- Study location
NCT03838900: Completed study of Diabetes Mellitus, Type 1, sponsored by Jaeb Center for Health Research.
NCT03838900 is a study of Diabetes Mellitus, Type 1 that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 1,212 participants, roughly in line with the 1,256-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03838900, a study of Diabetes Mellitus, Type 1, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- 1,212 participants
- Enrollment target
- 1
- Study location
Study Summary
An observational study to collect data on the efficacy, safety, usability, and quality of life/psychosocial effects of the Loop DIY automated insulin delivery system.
Primary Outcome
Number of DKA events and event outcomes on the Adverse Event and Device Issue - Loop survey. DKA events are defined as the development of ketones with a diagnosis of DKA by a medical provider.
Conditions Studied
Interventions
- DEVICE Loop
Study Locations (1)
Florida
- Jaeb Center for Health Research - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,212 participants |
| Start Date | 2019-01-17 |
| Est. Completion | 2020-04-25 |
What the finished NCT03838900 record still lists
NCT03838900 is an observational study that tracks outcomes without assigning an intervention. Its 1,212 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,256-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Loop is the first listed.
NCT03838900 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03838900 about?
NCT03838900 is a clinical study titled "The Loop Observational Study". An observational study to collect data on the efficacy, safety, usability, and quality of life/psychosocial effects of the Loop DIY automated insulin delivery system.
What is the current status of trial NCT03838900?
This trial is currently completed. The enrollment target is 1,212 participants. The study started on 2019-01-17. Estimated completion is 2020-04-25.
What conditions does trial NCT03838900 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT03838900?
The interventions under investigation include: Loop (DEVICE).
Who is sponsoring clinical trial NCT03838900?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03838900 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03838900's enrollment target sits among peer trials
1,212 5th of 118 higher than 114 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Genetics Of Autoimmunity In Type I Diabetes
RECRUITING
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Regulation of Brain Glucose Metabolism in Type 1 Diabetes
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI